期刊
THESCIENTIFICWORLDJOURNAL
卷 8, 期 -, 页码 909-919出版社
HINDAWI LTD
DOI: 10.1100/tsw.2008.117
关键词
cetuximab; epidermal growth factor receptor; Erbitux; head and neck cancer; lung cancer; targeted therapy
资金
- NIH/NCI [CA125541-02, CA129501]
- American Lung Association
- V-Foundation
- Respiratory Health Association of Chicago
- Kate McMullen Foundation
- University of Chicago Cancer Research Center
- NATIONAL CANCER INSTITUTE [R01CA129501, R01CA125541] Funding Source: NIH RePORTER
Cancers of the head and neck and of the lung are associated with high morbidity and mortality rates that have remained relatively unchanged for more than 3 decades, despite advances in radiation therapies and chemotherapies over the same time. It is generally believed that the efficacy of standard therapy regimens has reached a plateau for these cancers. The discovery of specific aberrant molecular signaling pathways in solid tumors has afforded promising new directions for newer targeted cancer therapeutics. Among these, the epidermal growth factor receptor (EGFR) shows promise as a therapeutic target. Clinical studies have demonstrated that this targeted approach provides clinically meaningful benefit. This article reviews EGFR-targeted therapies in use and in development, with a focus on the role of EGFR in the pathophysiology of head and neck and lung cancer, and new concepts being investigated to improve outcomes with these agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据